Harpoon Therapeutics Inc.
Harpoon Therapeutics, Inc is a clinical-stage immuno-oncology company designed for targeted penetration and destruction of solid tumors and hematologic malignancies and engineered to bind to human serum albumin for improved therapeutic schedule and patient convenience. The company annual revenue is 17.4 million USD and 171.5 million USD as on 2020. The headquarters is in USA.
Merck planning to buy Harpoon Therapeutics for 680 million USD and announced in January-2024.